|Day Low/High||75.85 / 77.85|
|52 Wk Low/High||62.66 / 94.98|
Wall Street woke up to another major deal. Here's what to watch from AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Let's look closer at the charts and indicators of ABBV.
U.S. equity futures drifted lower Tuesday, setting up the S&P 500 for its first three-day decline since early May, as investors peel back from recent record highs and take a defensive stance on risk ahead of this weekend's G20 Summit in Japan.
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
U.S. stock futures decline as investors take a defensive stance on risk ahead of this weekend's G-20 summit in Japan; Micron reports earnings Tuesday; FedEx, which also reports earnings, sues the U.S. government arguing new trade regulations put an 'impossible burden' on the company to monitor its shipments.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
- FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria
NORTH CHICAGO, Ill., June 20, 2019 /PRNewswire/ -- The board of directors of AbbVie Inc.
The narrative in the market is that we are waiting for the Fed decision on Wednesday -- but of course it's not that clear cut is it?
- Data from SELECT-EARLY and SELECT-COMPARE show a significantly higher proportion of patients treated with upadacitinib monotherapy or in combination with methotrexate (MTX) maintaining clinical remission compared with MTX or adalimumab plus MTX, respectively, at 48 weeks1,2
- Longer-term results from IMMhance showed 73 percent and 72 percent of patients treated with continuous SKYRIZI™ (risankizumab) experienced complete skin clearance (defined as sPGA 0 and PASI 100, respectively) at week 94, among patients who achieved sPGA 0/1 at week 28 
NORTH CHICAGO, Ill., June 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 40 th Annual Global Healthcare Conference on Wednesday, June 12, 2019.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
- Phase 3 data from CLL14 study were highlighted in an oral presentation (abstract #7502) today at ASCO and published in the New England Journal of Medicine - Patients treated with venetoclax plus obinutuzumab lived significantly longer without their...
- AbbVie to present more than 40 abstracts from its oncology pipeline at this year's ASCO and EHA medical meetings in June
We can't get a break under all those round numbers on the major indexes, yet, the Russell 2000 outperforms and the number of stocks making new lows mostly stays put.
Shares of Gilead Sciences fall after Goldman Sachs downgrades the stock to sell from neutral.
-Phase 3 INTELLANCE-1 study, conducted in collaboration with the RTOG Foundation, did not meet primary endpoint of overall survival at the interim analysis and demonstrated no survival benefit for patients receiving Depatux-M
Gainers trail losers in Cannabis sector action Thursday.
- FDA reviewed the submission under the Real-Time Oncology Review pilot program
MC10, Inc., a healthcare technology company specializing in wearable digital health sensors, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the companies are working together on clinical trials designed to...
NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that it has resolved U.
NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 21, 2019.
NORTH CHICAGO, Ill., May 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019.
- Approval based on results from clinical studies showing high rates of skin clearance at 16 weeks; this clearance was durable at one year with every 12-week dosing[1-4]
- Presentations include updates on ABBV-951, a subcutaneous infusion therapy for Parkinson's disease (PD), and elezanumab, a monoclonal antibody directed against repulsive guidance molecule A (RGMa) in multiple sclerosis (MS), among other data to be presented
AbbVie climbs after beating first-quarter estimates and raising full-year guidance.
As we have seen so far, in terms of market reaction, there is great reward at the point of sale in beating expectations.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.